1. Pronovost, P, Needham, D, Berenholtz, S, et al. An intervention to decrease catheter-related bloodstream infections in the ICU. New Engl J Med 2006;355:2725–2732.
2. Gerding, DN, Muto, CA, Owens, RC. Measures to control and prevent Clostridium difficile infection. Clin Infect Dis 2008;46:S43–S49.
3. Trick, WE, Temple, RS, Chen, D, Wright, MO, Solomon, SL, Peterson, LR. Patient colonization and environmental contamination by vancomycin-resistant enterococci in a rehabilitation facility. Arch Phys Med Rehab 2002;83:899–902.
4. Sethi, AK, Al-Nassir, WN, Nerandzic, MM, Donskey, CJ. Skin and environmental contamination with vancomycin-resistant enterococci in patients receiving oral metronidazole or oral vancomycin treatment for Clostridium difficile–associated disease. Infect Control Hosp Epidemiol 2009;30:13–17.
5. McDonald, LC, Owings, M, Jernigan, DB.
Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996–2003. Emerg Infect Dis 2006;12:409–415.
6. Dubberke, ER, Gerding, DN, Classen, D, et al. Strategies to prevent Clostridium difficile infections in acute care hospitals. Infect Control Hosp Epidemiol 2008;29(Suppl 1):S81–S92.
7. Stelfox, HT, Bates, DW, Redelmeier, DA. Safety of patients isolated for infection control. JAMA 2003;290:1899–1905.
8. Johnson, S, Clabots, CR, Linn, FV, Olson, MM, Peterson, LR, Gerding, DN. Nosocomial Clostridium difficile colonisation and disease. Lancet 1990;336:97–100.
9. Goldenberg, JZ, Ma, SS, Saxton, JD, et al. Probiotics for the prevention of Clostridium difficile–associated diarrhea in adults and children. Cochrane Libr 2013.
10. Lau, CS, Chamberlain, RS. Probiotics are effective at preventing Clostridium difficile–associated diarrhea: a systematic review and meta-analysis. Int J Gen Med 2016;9:27–37.
11. Johnson, S, Maziade, PJ, McFarland, LV, et al. Is primary prevention of Clostridium difficile infection possible with specific probiotics? Int J Infect Dis 2012;16:786–792.
12. Beausoleil, M, Fortier, N, Guenette, S, et al. Effect of a fermented milk combining Lactobacillus acidophilus CL1285 and Lactobacillus casei in the prevention of antibiotic-associated diarrhea: a randomized, double-blind, placebo-controlled trial. Canad J Gastroenterol 2007;21:732–736.
13. Sampalis, J, Psaradellis, E, Rampakakis, E. Efficacy of BioK+ CL1285 in the reduction of antibiotic-associated diarrhea–a placebo-controlled double-blind randomized, multi-center study. Arch Med Sci 2010;6:56–64.
14. Gao, XW, Mubasher, M, Fang, CY, Reifer, C, Miller, LE. Dose-response efficacy of a proprietary probiotic formula of Lactobacillus acidophilus CL1285 and Lactobacillus casei LBC80R for antibiotic-associated diarrhea and Clostridium difficile-associated diarrhea prophylaxis in adult patients. Am J Gastroenterol 2010;105:1636–1641.
15. Maziade, P-J, Andriessen, J, Pereira, P, Currie, B, Goldstein, E. Impact of adding prophylactic probiotics to a bundle of standard preventative measures for Clostridium difficile infections: enhanced and sustained decrease in the incidence and severity of infection at a community hospital. Curr Med Res Opin 2013;29:1341–1347.
16. Goldstein, EJ, Citron, DM, Claros, MC, Tyrrell, KL. Bacterial counts from five over-the-counter probiotics: are you getting what you paid for? Anaerobe 2014;25:1–4.
17. McDonald, LC, Coignard, B, Dubberke, E, Song, X, Horan, T, Kutty, PK. Recommendations for surveillance of Clostridium difficile–associated disease. Infect Control Hosp Epidemiol 2007;28:140–145.
18. Longtin, Y, Paquet-Bolduc, B, Gilca, R, et al. Effect of detecting and isolating Clostridium difficile carriers at hospital admission on the incidence of c difficile infections: a quasi-experimental controlled study. JAMA Intern Med 2016;176:796–804.
19. Song, X, Srinivasan, A, Plaut, D, Perl, TM. Effect of nosocomial vancomycin-resistant enterococcal bacteremia on mortality, length of stay, and costs. Infect Control Hosp Epidemiol 2003;24:251–256.
20. Averill, RF, McCullough, EC, Goldfield, N, Hughes, JS, Bonazelli, J, Bentley, L. 3M APR DRG classification system: methodology overview. Agency for Healthcare Research and Quality website. https://www.hcup-us.ahrq.gov/db/nation/nis/grp031_aprdrg_meth_ovrview.pdf. Published 2013. Accessed July 6, 2017.
21. Hernan, MA, Robins, JM. Per-protocol analyses of pragmatic trials. New Engl J Med 2017;377:1391–1398.
22. Weber, DJ, Rutala, WA, Miller, MB, Huslage, K, Sickbert-Bennett, E. Role of hospital surfaces in the transmission of emerging health care-associated pathogens: norovirus, Clostridium difficile, and Acinetobacter species. Am J Infect Control 2010;38:S25–S33.
23. Samore, MH, Venkataraman, L, DeGirolami, PC, Arbeit, RD, Karchmer, AW. Clinical and molecular epidemiology of sporadic and clustered cases of nosocomial Clostridium difficile diarrhea. Am J Med 1996;100:32–40.
24. Halpin, AL, McDonald, LC. The dawning of microbiome remediation for addressing antibiotic resistance. Clin Infect Dis 2016;62:1487–1488.
25. Freedberg, DE, Salmasian, H, Cohen, B, Abrams, JA, Larson, EL. Receipt of antibiotics in hospitalized patients and risk for Clostridium difficile infection in subsequent patients who occupy the same bed. JAMA Intern Med 2016;176:1801–1808.
26. Aroutcheva, A, Auclair, J, Frappier, M, et al. Importance of molecular methods to determine whether a probiotic is the source of lactobacillus bacteremia. Probiot Antimicrob Prot 2016;8:31–40.
27. McFarland, LV, Huang, Y, Wang, L, Malfertheiner, P. Systematic review and meta-analysis: multi-strain probiotics as adjunct therapy for Helicobacter pylori eradication and prevention of adverse events. United Eur Gastroen J 2015;4:546–561.
28. Johnston, BC, Ma, SS, Goldenberg, JZ, et al. Probiotics for the prevention of Clostridium difficile–associated diarrhea: a systematic review and meta-analysis. Ann Intern Med 2012;157:878–888.